Cambiar Aggressive Value ETF

CAMX

Market cap $59.7M

Overview Fund Activity

31.32 USD

-0.06

0.19%

At close Updated Sep 15, 4:00 PM EDT

1 day

-0.19%

5 days

-0.95%

1 month

-1.01%

3 months

1.62%

6 months

2.72%

Year to date

6.82%

1 year

7.59%

5 years

29.47%

10 years

29.47%

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

43% more funds holding

Funds holding: 7 [Q1] → 10 (+3) [Q2]

12% more capital invested

Capital invested by funds: $5.08M [Q1] → $5.69M (+$605K) [Q2]

0.68% more ownership

Funds ownership: 8.66% [Q1] → 9.34% (+0.68%) [Q2]

See Fund Rankings

Financial journalist opinion

Negative

ETF Trends

5 months ago

Delta Earnings Showcase 2025 Worries & Active ETF Opportunities

While many market sectors are being troubled by macroeconomic uncertainty, the travel sector may very well have it the worst. Given the rise in inflationary pressures and recession risks, it could be difficult to justify travel expenditures at the moment.

Neutral

PRNewsWire

1 year ago

Camurus announces positive Phase 3 results from the ACROINNOVA 2 study of octreotide SC depot (CAM2029) in acromegaly patients

Treatment well tolerated with a safety profile consistent with standard-of-care (SoC) Increased biochemical response rates (IGF-1 ≤ 1xULN) vs SoC at baseline Continuous improvement of acromegaly symptom and quality of life scores vs baseline Study results reinforce previously reported interim results from ACROINNOVA 21 LUND, Sweden , July 15, 2024 /PRNewswire/ -- Camurus (NASDAQ: CAMX) (STO: CAMX) today announced positive, final, topline results from the 52-week Phase 3 open-label ACROINNOVA 2 (NCT04125836) study, which evaluated safety and efficacy of the company's once-monthly octreotide subcutaneous (SC) depot (CAM2029). The study included a total of 135 patients with acromegaly who were biochemically controlled (IGF-1≤1xULN) or uncontrolled on stable doses of standard-of-care (SoC) with first generation somatostatin ligands (SRL) at screening; of these, 81 were new to study patients and 54 were roll-over patients from 24-week randomized treatment with octreotide SC depot or placebo (ACROINNOVA 1).

See News Rankings

Charts implemented using Lightweight Charts™

Cambiar Aggressive Value ETF CAMX Market cap $59.7M